Huntington's Disease
Conditions
Keywords
Neurodegenerative genetic disorder
Brief summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BN82451B versus placebo after oral administration twice daily (bid) for 28 days in patients with Huntington's Disease (HD).
Interventions
BN82451B capsule
Placebo capsule
Sponsors
Study design
Eligibility
Inclusion criteria
* Male subjects 20 to 70 years old (inclusive). * Provision of written informed consent prior to any study related procedures. In this study consent may be provided by the legal guardian or carer. * Confirmed symptomatic Huntington's Disease diagnosed based on clinical features (i.e. Diagnostic Confidence Level equal to 4) and presence of at least 36 cytosine adenine guanine (CAG) repeats in the Huntington gene as documented by a copy of a previous genetic test report. * Unified Huntington's Disease Rated Scale-Total Motor Score (UDHRS-TMS) greater than or equal to 15. * Ambulatory. * UDHRS-Total Functional Capacity (TFC) greater than or equal to 3 (i.e. Shoulson & Fahn Scale stages 1-3 inclusive. * Subjects on antipsychotic, antidepressant, anxiolytic and hypnotic therapy must have been on stable treatment 4 weeks prior to study drug start and during the study period. * Able to swallow study medication. * Able to perform Q-Motor tests. * If his partner is at risk of pregnancy, the subject agrees to use a condom or be abstinent for 14 days after the last intake of study drug.
Exclusion criteria
* Juvenile forms of Huntington's Disease. * Any form of chorea other than Huntington's Disease. * History of seizure, epilepsy or other convulsive disorder, with the exception of febrile seizures in childhood. * History of conditions susceptible to induce seizures such as severe traumatic brain injury, brain tumours, stroke. * History of neurosurgical procedure. * Current evidence or history (within 1 year of Baseline) of psychosis, hallucinations or delusions, including major depression with psychotic features, as defined in the Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR). Patients currently experiencing mild depression, or moderate depression which is adequately and appropriately treated in the judgement of the investigator, can participate if depression is not expected to interfere with study participation. * History of drug and/or alcohol abuse as per the DSM IV-TR criteria within 12 months prior to Baseline. * At imminent risk of self harm based on investigator's clinical judgment, with a yes answer on item 4 or 5 on the Columbia-Suicide Severity Rating Scale (CSSRS) questionnaire. * Mini Mental State Exam (MMSE) total score less than or equal to 23. * Used any investigational drugs within 30 days prior to Screening or 5 half lives, whichever is the longest. * Known allergy/sensitivity to the study drugs or their excipients. * A severe or ongoing unstable medical condition (e.g. cardiac, hepatic, renal, metabolic or endocrine). * Any clinically significant condition which, in the opinion of the investigator, would interfere with the trial evaluations or optimal participation in the trial. * Any significant laboratory results which, in the investigator's opinion, would not be compatible with study participation or represent a risk for subjects while in the study. * History of malignant disease within the 5 years prior to Screening (with the exception of basal cell and squamous cell carcinomas of the skin that have been completely excised, in situ prostate cancer with a normal prostate specific antigen). * An estimated Creatinine Clearance (CrCl) of less than 60 mL/minute (using the Cockcroft-Gault formula). * Alanine Aminotransferase (ALT)/Aspartate Aminotransferase (AST) values greater than or equal to 2 times the Upper Limit of Normal range (ULN) or both GGT and ALT values greater than three times the ULN. * Known history of hepatitis B or C or Human Immunodeficiency Virus (HIV) or positive serology at Screening. * Corrected QT interval using Bazett's correction (QTcB) greater than 450 ms or other clinically significant ECG findings. * Receiving tetrabenazine within 4 weeks prior to Baseline. * Taking the following prohibited medications/substances: Strong Cytochrome (CYP) 3A4 inhibitors and Strong CYP3A4 inducers (Wash out prior to Baseline 30 days or 5 half lives,whichever is the longest), CYP2B6 substrates, CYP1A2 substrates, CYP3A4 substrates, CYP2C19 substrates (assessed on a case by case basis)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Numbers of Patients Experiencing Treatment Emergent Adverse Events (TEAEs). | From Day 1 to end of study (a period of up to 7 weeks). | The safety and tolerability of BN82451B versus placebo was determined after oral administration b.i.d. for 28 days in patients with HD. Numbers of patients experiencing TEAEs, including information on seriousness, intensity, drug relationship and those leading to withdrawal are presented for all doses of BN82451B and placebo. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Area Under the Plasma Concentration Time Curve (AUC) | 0-12 hours on Days 1, 14 and 28 | The AUC was determined for BN82451B and its metabolites BN2468 and BN7167 within a dosage interval (0-12 hours) on Days 1, and 14 and 28. Day 1 data represent the AUC after the first dose (AUC\[0-12\]). The data for Days 14 and 28 (AUC\[τ,ss\]) represent the AUC at steady state at the initial cohort dose and following dose escalation, respectively. Data is presented for cohorts 1 and 2, as the study terminated prior to dosing of cohort 3. |
| Peak Plasma Concentration (Cmax) | Days 1, 14 and 28 | Cmax was determined for BN82451B and its metabolites BN2468 and BN7167 on Days 1, 14 and 28. Day 1 data represent the PK after the first dose (Cmax). The data for Days 14 and 28 represent the Cmax at steady state (Cmax,ss) at the initial cohort dose and following dose escalation, respectively. Data is presented for cohorts 1 and 2, as the study terminated prior to dosing of cohort 3. |
| Time to Peak Plasma Concentration (Tmax) | Days 1, 14 and 28 | Tmax is the empirical time of Cmax and was determined for BN82451B and its metabolites BN2468 and BN7167 on Days 1, 14 and 28. Day 1 data represent the PK after the first dose (Tmax). The data for Days 14 and 28 represent the Tmax at steady state (Tmax,ss) at the initial cohort dose and following dose escalation, respectively. Data is presented for cohorts 1 and 2, as the study terminated prior to dosing of cohort 3. |
| Change From Baseline to Day 28 in the Position-index as Determined by Choreomotography | Baseline (Day-1) to Day 28 | Choreatic (involuntary) movements were assessed using Choreomotography by calculating a position-index and orientation-index. Patients were asked to grasp and lift a device equipped with an electromagnetic sensor, and were asked to hold the device as stable as possible. Three dimensional (3D) changes in position (x, y and z) and orientation (roll, pitch and yaw) were recorded and used to calculate a position-index and an orientation-index. This method provided an objective measure of the involuntary movements. 5 trials of 20 seconds duration were performed with each hand, and the start and end of each trial was signalled by a cueing tone. The mean changes from Baseline to Day 28 in the position-index of the right and left hands are presented as raw data. The statistical analyses present geometric least squares (GLS) mean ratios in the original units. |
| Change From Baseline to Day 28 in the Orientation-index as Determined by Choreomotography | Baseline (Day -1) to Day 28 | Choreatic (involuntary) movements were assessed using Choreomotography by calculating a position-index and orientation-index. Patients were asked to grasp and lift a device equipped with an electromagnetic sensor, and were asked to hold the device as stable as possible. 3D changes in position (x, y and z) and orientation (roll, pitch and yaw) were recorded and used to calculate a position-index and an orientation-index. This method provided an objective measure of the involuntary movements. 5 trials of 20 seconds duration were performed with each hand, and the start and end of each trial was signalled by a cueing tone. The mean changes from Baseline to Day 28 in the orientation-index of the right and left hands are presented as raw data. The statistical analyses present GLS mean ratios in the original units. |
| Change From Baseline to Day 28 in the Mean Grip Force Variability as Determined by Manumotography | Baseline (Day -1) to Day 28 | The coordination of isometric grip forces in the precision grip between the thumb and index finger were assessed by Manumotography. Grip forces were assessed during grip initiation, object transport and in a static holding phase. Subjects were instructed to grasp and lift a device equipped with a force transducer and 3D position sensor in the precision grip between thumb and index finger and hold it stable adjacent to a marker 10 centimetres high. Grip forces and 3D position and orientation of the object were recorded. Mean isometric grip forces and grip force variability in the static phase (expressed as coefficient of variation = standard deviation/mean x 100 \[GFV-C\]) were calculated during a 15 second period. 5 trials of 20 seconds duration were performed with each hand. The mean changes from Baseline to Day 28 in the grip force variability of each hand are presented as raw data. The statistical analyses present GLS mean ratios in the original units. |
| Change From Baseline to Day 28 in the Mean Isometric Grip Forces as Determined by Manumotography | Baseline (Day -1) to Day 28 | The coordination of isometric grip forces in the precision grip between the thumb and index finger were assessed by Manumotography. Grip forces were assessed during grip initiation, object transport and in a static holding phase. Subjects were instructed to grasp and lift a device equipped with a force transducer and 3D position sensor in the precision grip between thumb and index finger and hold it stable adjacent to a marker 10 centimetres high. Grip forces and 3D position and orientation of the object were recorded. Mean isometric grip forces and grip force variability in the static phase (expressed as coefficient of variation = standard deviation/mean x 100 \[GFV-C\]) were calculated during a 15 second period. 5 trials of 20 seconds duration were performed with each hand. The mean changes from Baseline to Day 28 in the mean isometric grip forces of each hand are presented as raw data. The statistical analyses present GLS mean ratios in the original units. |
| Change From Baseline to Day 28 in the Mean Duration and Variability of Inter Onset Intervals (IOI) as Assessed by Digitomotography | Baseline (Day-1) to Day 28 | Digitomotography was used to assess the duration and the variability of tap IOI in an index finger speeded tapping task. The patient placed their hand on a hand rest with their index finger positioned on a force transducer, and recordings were started after practice runs. The patient was then instructed to finger tap as fast as possible between 2 auditory cues. The beginning of a tap was defined as a rise of the force by 0.05 N above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. 5 trials of 10 seconds duration were performed with each hand. The mean changes from Baseline to Day 28 in the duration and variability of IOI for the left and right hands are presented as raw data. The statistical analyses present GLS mean ratios in the original units. |
| Change From Baseline to Day 28 in the Mean Duration and Variability of Tap Durations (TD) as Assessed by Digitomotography | Baseline (Day -1) to Day 28 | Digitomotography was used to assess the duration and the variability of TD in an index finger speeded tapping task. The patient placed their hand on a hand rest with their index finger positioned on a force transducer, and recordings were started after practice runs. The patient was then instructed to finger tap as fast as possible between 2 auditory cues. The beginning of a tap was defined as a rise of the force by 0.05 N above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. 5 trials of 10 seconds duration were performed with each hand. The mean changes from Baseline to Day 28 in the duration and variability of TD for the left and right hands are presented a raw data. The statistical analyses present GLS mean ratios in the original units. |
| Change From Baseline to Day 28 in the Mean Duration and Variability of Inter Peak Intervals (IPI) as Assessed by Digitomotography | Baseline (Day -1) to Day 28 | Digitomotography was used to assess the duration and the variability of tap IPI in an index finger speeded tapping task. The patient placed their hand on a hand rest with their index finger positioned on a force transducer, and recordings were started after practice runs. The patient was then instructed to finger tap as fast as possible between 2 auditory cues. The beginning of a tap was defined as a rise of the force by 0.05 N above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. 5 trials of 10 seconds duration were performed with each hand. The mean changes from Baseline to Day 28 in the duration and variability of IPI for the left and right hands are presented as raw data. The statistical analyses present GLS mean ratios in the original units. |
| Change From Baseline to Day 28 in the Mean Duration and Variability of Inter Tap Intervals (ITI) as Assessed by Digitomotography | Baseline (Day-1) to Day 28 | Digitomotography was used to assess the duration and the variability of ITI in an index finger speeded tapping task. The patient placed their hand on a hand rest with their index finger positioned on a force transducer, and recordings were started after practice runs. The patient was then instructed to finger tap as fast as possible between 2 auditory cues. The beginning of a tap was defined as a rise of the force by 0.05 N above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. 5 trials of 10 seconds duration were performed with each hand. The mean changes from Baseline to Day 28 in the duration and variability of ITI for the left and right hands are presented as raw data. The statistical analyses present GLS mean ratios in the original units. |
| Change From Baseline to Day 28 in the Mean Variability of Peak Tapping Forces (TF) as Assessed by Digitomotography | Baseline (Day-1) to Day 28 | Digitomotography was used to assess the duration and the variability of TD in an index finger speeded tapping task. The patient placed their hand on a hand rest with their index finger positioned on a force transducer, and recordings were started after practice runs. The patient was then instructed to finger tap as fast as possible between 2 auditory cues. The beginning of a tap was defined as a rise of the force by 0.05 N above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. 5 trials of 10 seconds duration were performed with each hand. The mean changes from Baseline to Day 28 in the variability of TF for the left and right hands are presented as raw data. The statistical analyses present GLS mean ratios in the original units. |
| Change From Baseline to Day 28 in the Mean Tapping Frequency (Freq) as Assessed by Digitomotography | Baseline (Day-1) to Day 28 | Digitomotography was used to assess the duration and the variability of TD in an index finger speeded tapping task. The patient placed their hand on a hand rest with their index finger positioned on a force transducer, and recordings were started after practice runs. The patient was then instructed to finger tap as fast as possible between 2 auditory cues. The beginning of a tap was defined as a rise of the force by 0.05 N above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. 5 trials of 10 seconds duration were performed with each hand. The tapping frequency was calculated as the number of taps between the onsets of the first and the last tap divided by the time in between. The mean changes from Baseline to Day 28 in the tapping frequency for the left and right hands are presented as raw data. The statistical analyses present GLS mean ratios in the original units. |
| Change From Baseline to Day 28 in the Mean Duration and Variability of IOI as Assessed by Dysdiadochomotography | Baseline (Day -1) to Day 28 | Dysdiadochomotography was used to assess the regularity of hand taps performed when alternating between the palm and dorsal surface of the hand performing a repetitive pronation/supination movement. The force and duration of the hand taps were recorded, with their hand positioned on a force transducer, and recordings were started after practice runs. The patient was then instructed to hand tap as fast as possible between 2 auditory cues. The beginning of a tap was defined as a rise of the force by 0.05 N above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. 5 trials of 10 seconds duration were performed with each hand. The mean changes from Baseline to Day 28 in the duration and variability of IOI for the left and right hands are presented as raw data. The statistical analyses present GLS mean ratios in the original units. |
| Change From Baseline to Day 28 in the Mean Duration and Variability of TD as Assessed by Dysdiadochomotography | Baseline (Day -1) to Day 28 | Dysdiadochomotography was used to assess the regularity of hand taps performed when alternating between the palm and dorsal surface of the hand performing a repetitive pronation/supination movement. The force and duration of the hand taps were recorded, with their hand positioned on a force transducer, and recordings were started after practice runs. The patient was then instructed to hand tap as fast as possible between 2 auditory cues. The beginning of a tap was defined as a rise of the force by 0.05 N above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. 5 trials of 10 seconds duration were performed with each hand. The mean changes from Baseline to Day 28 in the duration and variability of TD for the left and right hands are presented as raw data. The statistical analyses present GLS mean ratios in the original units. |
| Change From Baseline to Day 28 in the Mean Duration and Variability of IPI as Assessed by Dysdiadochomotography | Baseline (Day-1) to Day 28 | Dysdiadochomotography was used to assess the regularity of hand taps performed when alternating between the palm and dorsal surface of the hand performing a repetitive pronation/supination movement. The force and duration of the hand taps were recorded, with their hand positioned on a force transducer, and recordings were started after practice runs. The patient was then instructed to hand tap as fast as possible between 2 auditory cues. The beginning of a tap was defined as a rise of the force by 0.05 N above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. 5 trials of 10 seconds duration were performed with each hand. The mean changes from Baseline to Day 28 in the duration and variability of IPI for the left and right hands are presented as raw data. The statistical analyses present GLS mean ratios in the original units. |
| Change From Baseline to Day 28 in the Mean Duration and Variability of ITI as Assessed by Dysdiadochomotography | Baseline (Day -1) to Day 28 | Dysdiadochomotography was used to assess the regularity of hand taps performed when alternating between the palm and dorsal surface of the hand performing a repetitive pronation/supination movement. The force and duration of the hand taps were recorded, with their hand positioned on a force transducer, and recordings were started after practice runs. The patient was then instructed to hand tap as fast as possible between 2 auditory cues. The beginning of a tap was defined as a rise of the force by 0.05 N above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. 5 trials of 10 seconds duration were performed with each hand. The mean changes from Baseline to Day 28 in the duration and variability of ITI for the left and right hands are presented as raw data. The statistical analyses present GLS mean ratios in the original units. |
| Change From Baseline to Day 28 in the Mean Variability of Peak TF as Assessed by Dysdiadochomotography | Baseline (Day-1) to Day 28 | Dysdiadochomotography was used to assess the regularity of hand taps performed when alternating between the palm and dorsal surface of the hand performing a repetitive pronation/supination movement. The force and duration of the hand taps were recorded, with their hand positioned on a force transducer, and recordings were started after practice runs. The patient was then instructed to hand tap as fast as possible between 2 auditory cues. The beginning of a tap was defined as a rise of the force by 0.05 N above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. 5 trials of 10 seconds duration were performed with each hand. The mean changes from Baseline to Day 28 in the variability of TF for the left and right hands are presented as raw data. The statistical analyses present GLS mean ratios in the original units. |
| Change From Baseline to Day 28 in the Mean Tapping Frequency as Assessed by Dysdiadochomotography | Baseline (Day -1) to Day 28 | Dysdiadochomotography was used to assess the regularity of hand taps performed when alternating between the palm and dorsal surface of the hand performing a repetitive pronation/supination movement. The force and duration of the hand taps were recorded, with their hand positioned on a force transducer, and recordings were started after practice runs. The patient was then instructed to hand tap as fast as possible between 2 auditory cues. The beginning of a tap was defined as a rise of the force by 0.05 N above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. 5 trials of 10 seconds duration were performed with each hand. The tapping frequency was calculated as the number of taps between the onsets of the first and the last tap divided by the time in between. The mean changes from Baseline to Day 28 in the tapping frequency for the left and right hands are presented as raw data. GLS mean ratios are in original units. |
| Change From Baseline to Day 28 in the Mean Duration and Variability of IOI as Assessed by Pedomotography | Baseline (Day-1) to Day 28 | Pedomotography was used to assess the tap duration and variability in a foot speeded tapping task. The patient placed their foot on the foot device such that the ball of the foot was positioned above a force transducer, and recordings were started after practice runs. The patient was then instructed to foot tap as fast as possible between 2 auditory cues. The beginning of a tap was defined as a rise of the force by 0.05 N above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. 5 trials of 10 seconds duration were performed with each foot. The mean changes from Baseline to Day 28 in the duration and variability of IOI for the left and right feet are presented as raw data. The statistical analyses present GLS mean ratios in the original units. |
| Change From Baseline to Day 28 in the Mean Duration and Variability of TD as Assessed by Pedomotography | Baseline (Day-1) to Day 28 | Pedomotography was used to assess the tap duration and variability in a foot speeded tapping task. The patient placed their foot on the foot device such that the ball of the foot was positioned above a force transducer, and recordings were started after practice runs. The patient was then instructed to foot tap as fast as possible between 2 auditory cues. The patient was then instructed to foot tap as fast as possible between 2 auditory cues. The beginning of a tap was defined as a rise of the force by 0.05 N above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. 5 trials of 10 seconds duration were performed with each foot. The mean changes from Baseline to Day 28 in the duration and variability of TD for the left and right feet are presented as raw data. The statistical analyses present GLS mean ratios in the original units. |
| Change From Baseline to Day 28 in the Mean Duration and Variability of IPI as Assessed by Pedomotography | Baseline (Day-1) to Day 28 | Pedomotography was used to assess the tap duration and variability in a foot speeded tapping task. The patient placed their foot on the foot device such that the ball of the foot was positioned above a force transducer, and recordings were started after practice runs. The patient was then instructed to foot tap as fast as possible between 2 auditory cues. The beginning of a tap was defined as a rise of the force by 0.05 N above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. 5 trials of 10 seconds duration were performed with each foot. The mean changes from Baseline to Day 28 in the duration and variability of IPI for the left and right feet are presented as raw data. The statistical analyses present GLS mean ratios in the original units. |
| Change From Baseline to Day 28 in the Mean Duration and Variability of ITI as Assessed by Pedomotography | Baseline (Day-1) to Day 28 | Pedomotography was used to assess the tap duration and variability in a foot speeded tapping task. The patient placed their foot on the foot device such that the ball of the foot was positioned above a force transducer, and recordings were started after practice runs. The patient was then instructed to foot tap as fast as possible between 2 auditory cues. The beginning of a tap was defined as a rise of the force by 0.05 N above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. 5 trials of 10 seconds duration were performed with each foot. The mean changes from Baseline to Day 28 in the duration and variability of ITI for the left and right feet are presented as raw data. The statistical analyses present GLS mean ratios in the original units. |
| Change From Baseline to Day 28 in the Mean Variability of Peak TF as Assessed by Pedomotography | Baseline (Day -1) to Day 28 | Pedomotography was used to assess the tap duration and variability in a foot speeded tapping task. The patient placed their foot on the foot device such that the ball of the foot was positioned above a force transducer, and recordings were started after practice runs. The patient was then instructed to foot tap as fast as possible between 2 auditory cues. The beginning of a tap was defined as a rise of the force by 0.05 N above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. 5 trials of 10 seconds duration were performed with each foot. The mean changes from Baseline to Day 28 in the variability of TF for the left and right feet are presented as raw data. The statistical analyses present GLS mean ratios in the original units. |
| Change From Baseline to Day 28 in the Mean Tapping Frequency as Assessed by Pedomotography | Baseline (Day -1) to Day 28 | Pedomotography was used to assess the tap duration and variability in a foot speeded tapping task. The patient placed their foot on the foot device such that the ball of the foot was positioned above a force transducer, and recordings were started after practice runs. The patient was then instructed to foot tap as fast as possible between 2 auditory cues. The beginning of a tap was defined as a rise of the force by 0.05 N above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. 5 trials of 10 seconds duration were performed with each foot. The tapping frequency was calculated as the number of taps between the onsets of the first and the last tap divided by the time in between. The mean changes from Baseline to Day 28 in the tapping frequency for the left and right hands are presented as raw data. The statistical analyses present GLS mean ratios in the original units. |
Countries
Germany
Participant flow
Recruitment details
The study was a double blind, placebo controlled, randomised, sequential dose ranging repeated dose trial where patients were recruited to a single study centre in Germany. It was planned to enrol 30 patients (10 in each of 3 cohorts). Patients were enrolled to the study from 1 September 2014 until early termination of the study on 31 March 2016.
Pre-assignment details
Male patients 20-70 years with a documented diagnosis of Huntington's Disease (HD) with at least 36 cytosine adenine guanine repeats in the Huntington gene were screened. Eligibile patients needed to meet defined criteria during quantitative motor function assessments. 25 patients were screened, 17 were enrolled and randomised to treatment.
Participants by arm
| Arm | Count |
|---|---|
| BN82451B Patients were randomised to receive oral study medication, BN82451B, b.i.d. from Day 1 to Day 27, under double-blinded conditions. On Day 28 only one morning dose of BN82451B was administered. It was planned for patients to be assigned to 3 cohorts to receive 3 dose levels ranging between 40 and 80 milligrams (mg) b.i.d.
For cohort 1, 40 mg BN82451B b.i.d. was administered during the first 14 days. If this dose was well tolerated then it was increased to 60 mg b.i.d. for 13 days and one morning dose of 60 mg on Day 28.
For cohort 2, 60 mg BN82451B b.i.d. was administered during the first 14 days. If 60 mg b.i.d was well tolerated then it was increased to 80 mg b.i.d. for 13 days and one morning dose of 80 mg on Day 28.
For cohort 3 it was planned to administer 80 mg BN82451B b.i.d for 27 days with one morning dose of 80 mg on Day 28. The study was terminated early before completion of cohort 2. | 14 |
| Placebo Patients were randomised to receive oral placebo b.i.d. from Day 1 to Day 27, under double-blinded conditions. On Day 28 only one morning dose of placebo was administered. It was planned for patients to be assigned to 3 cohorts to receive 3 dose levels ranging between 40 and 80 mg b.i.d.
For cohort 1, 40 mg placebo b.i.d. was administered during the first 14 days. If this dose was well tolerated then it was increased to 60 mg b.i.d. for 13 days and one morning dose of 60 mg on Day 28.
For cohort 2, 60 mg placebo b.i.d. was administered during the first 14 days. If 60 mg b.i.d was well tolerated then it was increased to 80 mg b.i.d. for 13 days and one morning dose of 80 mg on Day 28.
For cohort 3 it was planned to administer 80 mg placebo b.i.d for 27 days with one morning dose of 80 mg on Day 28. The study was terminated early before completion of cohort 2. | 3 |
| Total Title | 17 |
| Total | 34 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 5 | 0 |
Baseline characteristics
| Characteristic | BN82451B | Placebo | Total Title |
|---|---|---|---|
| Age, Continuous | 46.6 years STANDARD_DEVIATION 14.4 | 50.0 years STANDARD_DEVIATION 8.7 | 46.6 years STANDARD_DEVIATION 14.4 |
| Sex: Female, Male Female | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Male | 14 Participants | 3 Participants | 17 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 11 / 14 | 2 / 3 |
| serious Total, serious adverse events | 0 / 14 | 0 / 3 |
Outcome results
Numbers of Patients Experiencing Treatment Emergent Adverse Events (TEAEs).
The safety and tolerability of BN82451B versus placebo was determined after oral administration b.i.d. for 28 days in patients with HD. Numbers of patients experiencing TEAEs, including information on seriousness, intensity, drug relationship and those leading to withdrawal are presented for all doses of BN82451B and placebo.
Time frame: From Day 1 to end of study (a period of up to 7 weeks).
Population: The Safety Population consisted of all randomised patients who received at least one dose of study medication.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| BN82451B | Numbers of Patients Experiencing Treatment Emergent Adverse Events (TEAEs). | Patients with any TEAEs | 11 Participants |
| BN82451B | Numbers of Patients Experiencing Treatment Emergent Adverse Events (TEAEs). | Patients with any serious TEAE | 0 Participants |
| BN82451B | Numbers of Patients Experiencing Treatment Emergent Adverse Events (TEAEs). | Patients with at least 1 severe TEAE | 0 Participants |
| BN82451B | Numbers of Patients Experiencing Treatment Emergent Adverse Events (TEAEs). | Patients with at least 1 moderate TEAE | 8 Participants |
| BN82451B | Numbers of Patients Experiencing Treatment Emergent Adverse Events (TEAEs). | Patients with at least 1 mild TEAE | 11 Participants |
| BN82451B | Numbers of Patients Experiencing Treatment Emergent Adverse Events (TEAEs). | Patients with TEAEs related to study medication | 9 Participants |
| BN82451B | Numbers of Patients Experiencing Treatment Emergent Adverse Events (TEAEs). | Patients with TEAEs leading to withdrawal | 5 Participants |
| BN82451B | Numbers of Patients Experiencing Treatment Emergent Adverse Events (TEAEs). | Patients with any TEAEs leading to death | 0 Participants |
| Placebo | Numbers of Patients Experiencing Treatment Emergent Adverse Events (TEAEs). | Patients with any TEAEs leading to death | 0 Participants |
| Placebo | Numbers of Patients Experiencing Treatment Emergent Adverse Events (TEAEs). | Patients with any TEAEs | 2 Participants |
| Placebo | Numbers of Patients Experiencing Treatment Emergent Adverse Events (TEAEs). | Patients with at least 1 mild TEAE | 1 Participants |
| Placebo | Numbers of Patients Experiencing Treatment Emergent Adverse Events (TEAEs). | Patients with any serious TEAE | 0 Participants |
| Placebo | Numbers of Patients Experiencing Treatment Emergent Adverse Events (TEAEs). | Patients with TEAEs leading to withdrawal | 0 Participants |
| Placebo | Numbers of Patients Experiencing Treatment Emergent Adverse Events (TEAEs). | Patients with at least 1 severe TEAE | 0 Participants |
| Placebo | Numbers of Patients Experiencing Treatment Emergent Adverse Events (TEAEs). | Patients with TEAEs related to study medication | 0 Participants |
| Placebo | Numbers of Patients Experiencing Treatment Emergent Adverse Events (TEAEs). | Patients with at least 1 moderate TEAE | 1 Participants |
Area Under the Plasma Concentration Time Curve (AUC)
The AUC was determined for BN82451B and its metabolites BN2468 and BN7167 within a dosage interval (0-12 hours) on Days 1, and 14 and 28. Day 1 data represent the AUC after the first dose (AUC\[0-12\]). The data for Days 14 and 28 (AUC\[τ,ss\]) represent the AUC at steady state at the initial cohort dose and following dose escalation, respectively. Data is presented for cohorts 1 and 2, as the study terminated prior to dosing of cohort 3.
Time frame: 0-12 hours on Days 1, 14 and 28
Population: The PK population consisted of all subjects from the safety population who had no major protocol deviations affecting the PK variables and who had a sufficient number of plasma BN82451B concentrations to estimate the main PK parameters.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| BN82451B | Area Under the Plasma Concentration Time Curve (AUC) | Day 14 BN82451B AUCτ,ss | 1521.11 hours*nanograms per millilitre (h*ng/mL) | Standard Deviation 593.22 |
| BN82451B | Area Under the Plasma Concentration Time Curve (AUC) | Day 1 BN82451B AUC(0-12) | 512.93 hours*nanograms per millilitre (h*ng/mL) | Standard Deviation 112.53 |
| BN82451B | Area Under the Plasma Concentration Time Curve (AUC) | Day 14 BN7167 AUC(τ,ss) | 33.39 hours*nanograms per millilitre (h*ng/mL) | Standard Deviation 20.08 |
| BN82451B | Area Under the Plasma Concentration Time Curve (AUC) | Day 28 BN2468 AUC(τ,ss) | 1509.67 hours*nanograms per millilitre (h*ng/mL) | Standard Deviation 105.94 |
| BN82451B | Area Under the Plasma Concentration Time Curve (AUC) | Day 28 BN82451B AUC(τ,ss) | 2357.95 hours*nanograms per millilitre (h*ng/mL) | Standard Deviation 977.74 |
| BN82451B | Area Under the Plasma Concentration Time Curve (AUC) | Day 1 BN2468 AUC(0-12) | 90.66 hours*nanograms per millilitre (h*ng/mL) | Standard Deviation 40.68 |
| BN82451B | Area Under the Plasma Concentration Time Curve (AUC) | Day 1 BN7167 AUC(0-12) | 16.82 hours*nanograms per millilitre (h*ng/mL) | Standard Deviation 9.01 |
| BN82451B | Area Under the Plasma Concentration Time Curve (AUC) | Day 14 BN2468 AUC(τ,ss) | 735.51 hours*nanograms per millilitre (h*ng/mL) | Standard Deviation 203.91 |
| BN82451B | Area Under the Plasma Concentration Time Curve (AUC) | Day 28 BN7167 AUC(τ,ss) | 34.64 hours*nanograms per millilitre (h*ng/mL) | Standard Deviation 16.05 |
| Placebo | Area Under the Plasma Concentration Time Curve (AUC) | Day 28 BN7167 AUC(τ,ss) | 63.81 hours*nanograms per millilitre (h*ng/mL) | Standard Deviation 57.7 |
| Placebo | Area Under the Plasma Concentration Time Curve (AUC) | Day 14 BN2468 AUC(τ,ss) | 1531.00 hours*nanograms per millilitre (h*ng/mL) | Standard Deviation 412.43 |
| Placebo | Area Under the Plasma Concentration Time Curve (AUC) | Day 1 BN82451B AUC(0-12) | 783.78 hours*nanograms per millilitre (h*ng/mL) | Standard Deviation 144.45 |
| Placebo | Area Under the Plasma Concentration Time Curve (AUC) | Day 1 BN7167 AUC(0-12) | 31.67 hours*nanograms per millilitre (h*ng/mL) | Standard Deviation 24.63 |
| Placebo | Area Under the Plasma Concentration Time Curve (AUC) | Day 14 BN82451B AUCτ,ss | 2594.05 hours*nanograms per millilitre (h*ng/mL) | Standard Deviation 1077.08 |
| Placebo | Area Under the Plasma Concentration Time Curve (AUC) | Day 14 BN7167 AUC(τ,ss) | 46.73 hours*nanograms per millilitre (h*ng/mL) | Standard Deviation 36.76 |
| Placebo | Area Under the Plasma Concentration Time Curve (AUC) | Day 28 BN82451B AUC(τ,ss) | 3313.45 hours*nanograms per millilitre (h*ng/mL) | Standard Deviation 1517.6 |
| Placebo | Area Under the Plasma Concentration Time Curve (AUC) | Day 28 BN2468 AUC(τ,ss) | 1936.35 hours*nanograms per millilitre (h*ng/mL) | Standard Deviation 569.97 |
Change From Baseline to Day 28 in the Mean Duration and Variability of Inter Onset Intervals (IOI) as Assessed by Digitomotography
Digitomotography was used to assess the duration and the variability of tap IOI in an index finger speeded tapping task. The patient placed their hand on a hand rest with their index finger positioned on a force transducer, and recordings were started after practice runs. The patient was then instructed to finger tap as fast as possible between 2 auditory cues. The beginning of a tap was defined as a rise of the force by 0.05 N above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. 5 trials of 10 seconds duration were performed with each hand. The mean changes from Baseline to Day 28 in the duration and variability of IOI for the left and right hands are presented as raw data. The statistical analyses present GLS mean ratios in the original units.
Time frame: Baseline (Day-1) to Day 28
Population: The PD population consisted of all subjects from the safety population who have not reported major protocol violations impacting Q-motor evaluation and who have a Q-motor evaluation assessed both at Baseline (Day -1) and at one post baseline visit.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of Inter Onset Intervals (IOI) as Assessed by Digitomotography | Left finger IOI variability | 0.039 seconds | Standard Deviation 0.048 |
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of Inter Onset Intervals (IOI) as Assessed by Digitomotography | Right finger IOI variability | 0.057 seconds | Standard Deviation 0.062 |
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of Inter Onset Intervals (IOI) as Assessed by Digitomotography | Left finger IOI duration | 0.088 seconds | Standard Deviation 0.075 |
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of Inter Onset Intervals (IOI) as Assessed by Digitomotography | Right finger IOI duration | 0.069 seconds | Standard Deviation 0.059 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of Inter Onset Intervals (IOI) as Assessed by Digitomotography | Right finger IOI duration | 0.032 seconds | Standard Deviation 0.031 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of Inter Onset Intervals (IOI) as Assessed by Digitomotography | Left finger IOI variability | -0.009 seconds | Standard Deviation 0.002 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of Inter Onset Intervals (IOI) as Assessed by Digitomotography | Left finger IOI duration | -0.015 seconds | Standard Deviation 0.041 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of Inter Onset Intervals (IOI) as Assessed by Digitomotography | Right finger IOI variability | 0.038 seconds | Standard Deviation 0.049 |
Change From Baseline to Day 28 in the Mean Duration and Variability of Inter Peak Intervals (IPI) as Assessed by Digitomotography
Digitomotography was used to assess the duration and the variability of tap IPI in an index finger speeded tapping task. The patient placed their hand on a hand rest with their index finger positioned on a force transducer, and recordings were started after practice runs. The patient was then instructed to finger tap as fast as possible between 2 auditory cues. The beginning of a tap was defined as a rise of the force by 0.05 N above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. 5 trials of 10 seconds duration were performed with each hand. The mean changes from Baseline to Day 28 in the duration and variability of IPI for the left and right hands are presented as raw data. The statistical analyses present GLS mean ratios in the original units.
Time frame: Baseline (Day -1) to Day 28
Population: The PD population consisted of all subjects from the safety population who have not reported major protocol violations impacting Q-motor evaluation and who have a Q-motor evaluation assessed both at Baseline (Day -1) and at one post baseline visit.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of Inter Peak Intervals (IPI) as Assessed by Digitomotography | Left finger IPI variability | 0.040 seconds | Standard Deviation 0.049 |
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of Inter Peak Intervals (IPI) as Assessed by Digitomotography | Right finger IPI variability | 0.057 seconds | Standard Deviation 0.067 |
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of Inter Peak Intervals (IPI) as Assessed by Digitomotography | Left finger IPI duration | 0.088 seconds | Standard Deviation 0.076 |
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of Inter Peak Intervals (IPI) as Assessed by Digitomotography | Right finger IPI duration | 0.069 seconds | Standard Deviation 0.059 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of Inter Peak Intervals (IPI) as Assessed by Digitomotography | Right finger IPI duration | 0.031 seconds | Standard Deviation 0.03 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of Inter Peak Intervals (IPI) as Assessed by Digitomotography | Left finger IPI variability | -0.009 seconds | Standard Deviation 0.007 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of Inter Peak Intervals (IPI) as Assessed by Digitomotography | Left finger IPI duration | -0.017 seconds | Standard Deviation 0.042 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of Inter Peak Intervals (IPI) as Assessed by Digitomotography | Right finger IPI variability | 0.038 seconds | Standard Deviation 0.044 |
Change From Baseline to Day 28 in the Mean Duration and Variability of Inter Tap Intervals (ITI) as Assessed by Digitomotography
Digitomotography was used to assess the duration and the variability of ITI in an index finger speeded tapping task. The patient placed their hand on a hand rest with their index finger positioned on a force transducer, and recordings were started after practice runs. The patient was then instructed to finger tap as fast as possible between 2 auditory cues. The beginning of a tap was defined as a rise of the force by 0.05 N above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. 5 trials of 10 seconds duration were performed with each hand. The mean changes from Baseline to Day 28 in the duration and variability of ITI for the left and right hands are presented as raw data. The statistical analyses present GLS mean ratios in the original units.
Time frame: Baseline (Day-1) to Day 28
Population: The PD population consisted of all subjects from the safety population who have not reported major protocol violations impacting Q-motor evaluation and who have a Q-motor evaluation assessed both at Baseline (Day -1) and at one post baseline visit.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of Inter Tap Intervals (ITI) as Assessed by Digitomotography | Left finger ITI Variability | 0.041 seconds | Standard Deviation 0.05 |
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of Inter Tap Intervals (ITI) as Assessed by Digitomotography | Right finger ITI Variability | 0.053 seconds | Standard Deviation 0.068 |
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of Inter Tap Intervals (ITI) as Assessed by Digitomotography | Right finger ITI Duration | 0.056 seconds | Standard Deviation 0.048 |
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of Inter Tap Intervals (ITI) as Assessed by Digitomotography | Left finger ITI Duration | 0.078 seconds | Standard Deviation 0.076 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of Inter Tap Intervals (ITI) as Assessed by Digitomotography | Right finger ITI Duration | 0.03 seconds | Standard Deviation 0.046 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of Inter Tap Intervals (ITI) as Assessed by Digitomotography | Left finger ITI Variability | -0.007 seconds | Standard Deviation 0.01 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of Inter Tap Intervals (ITI) as Assessed by Digitomotography | Right finger ITI Variability | 0.03 seconds | Standard Deviation 0.034 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of Inter Tap Intervals (ITI) as Assessed by Digitomotography | Left finger ITI Duration | -0.005 seconds | Standard Deviation 0.006 |
Change From Baseline to Day 28 in the Mean Duration and Variability of IOI as Assessed by Dysdiadochomotography
Dysdiadochomotography was used to assess the regularity of hand taps performed when alternating between the palm and dorsal surface of the hand performing a repetitive pronation/supination movement. The force and duration of the hand taps were recorded, with their hand positioned on a force transducer, and recordings were started after practice runs. The patient was then instructed to hand tap as fast as possible between 2 auditory cues. The beginning of a tap was defined as a rise of the force by 0.05 N above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. 5 trials of 10 seconds duration were performed with each hand. The mean changes from Baseline to Day 28 in the duration and variability of IOI for the left and right hands are presented as raw data. The statistical analyses present GLS mean ratios in the original units.
Time frame: Baseline (Day -1) to Day 28
Population: The PD population consisted of all subjects from the safety population who have not reported major protocol violations impacting Q-motor evaluation and who have a Q-motor evaluation assessed both at Baseline (Day -1) and at one post baseline visit.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of IOI as Assessed by Dysdiadochomotography | Right hand IOI variability | 0.031 seconds | Standard Deviation 0.094 |
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of IOI as Assessed by Dysdiadochomotography | Left hand IOI variability | 0.032 seconds | Standard Deviation 0.135 |
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of IOI as Assessed by Dysdiadochomotography | Left hand IOI duration | 0.054 seconds | Standard Deviation 0.114 |
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of IOI as Assessed by Dysdiadochomotography | Right hand IOI duration | 0.074 seconds | Standard Deviation 0.101 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of IOI as Assessed by Dysdiadochomotography | Right hand IOI variability | 0.163 seconds | Standard Deviation 0.276 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of IOI as Assessed by Dysdiadochomotography | Right hand IOI duration | 0.074 seconds | Standard Deviation 0.132 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of IOI as Assessed by Dysdiadochomotography | Left hand IOI duration | 0.028 seconds | Standard Deviation 0.043 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of IOI as Assessed by Dysdiadochomotography | Left hand IOI variability | 0.036 seconds | Standard Deviation 0.023 |
Change From Baseline to Day 28 in the Mean Duration and Variability of IOI as Assessed by Pedomotography
Pedomotography was used to assess the tap duration and variability in a foot speeded tapping task. The patient placed their foot on the foot device such that the ball of the foot was positioned above a force transducer, and recordings were started after practice runs. The patient was then instructed to foot tap as fast as possible between 2 auditory cues. The beginning of a tap was defined as a rise of the force by 0.05 N above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. 5 trials of 10 seconds duration were performed with each foot. The mean changes from Baseline to Day 28 in the duration and variability of IOI for the left and right feet are presented as raw data. The statistical analyses present GLS mean ratios in the original units.
Time frame: Baseline (Day-1) to Day 28
Population: The PD population consisted of all subjects from the safety population who have not reported major protocol violations impacting Q-motor evaluation and who have a Q-motor evaluation assessed both at Baseline (Day -1) and at one post baseline visit.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of IOI as Assessed by Pedomotography | Right foot IOI variability | 0.120 seconds | Standard Deviation 0.177 |
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of IOI as Assessed by Pedomotography | Left foot IOI variability | 0.146 seconds | Standard Deviation 0.353 |
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of IOI as Assessed by Pedomotography | Left foot IOI duration | 0.109 seconds | Standard Deviation 0.354 |
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of IOI as Assessed by Pedomotography | Right foot IOI duration | 0.267 seconds | Standard Deviation 0.461 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of IOI as Assessed by Pedomotography | Left foot IOI duration | -0.123 seconds | Standard Deviation 0.199 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of IOI as Assessed by Pedomotography | Left foot IOI variability | -0.1 seconds | Standard Deviation 0.122 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of IOI as Assessed by Pedomotography | Right foot IOI variability | 0.090 seconds | Standard Deviation 0.15 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of IOI as Assessed by Pedomotography | Right foot IOI duration | 0.075 seconds | Standard Deviation 0.164 |
Change From Baseline to Day 28 in the Mean Duration and Variability of IPI as Assessed by Dysdiadochomotography
Dysdiadochomotography was used to assess the regularity of hand taps performed when alternating between the palm and dorsal surface of the hand performing a repetitive pronation/supination movement. The force and duration of the hand taps were recorded, with their hand positioned on a force transducer, and recordings were started after practice runs. The patient was then instructed to hand tap as fast as possible between 2 auditory cues. The beginning of a tap was defined as a rise of the force by 0.05 N above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. 5 trials of 10 seconds duration were performed with each hand. The mean changes from Baseline to Day 28 in the duration and variability of IPI for the left and right hands are presented as raw data. The statistical analyses present GLS mean ratios in the original units.
Time frame: Baseline (Day-1) to Day 28
Population: The PD population consisted of all subjects from the safety population who have not reported major protocol violations impacting Q-motor evaluation and who have a Q-motor evaluation assessed both at Baseline (Day -1) and at one post baseline visit.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of IPI as Assessed by Dysdiadochomotography | Left hand IPI variability | 0.045 seconds | Standard Deviation 0.124 |
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of IPI as Assessed by Dysdiadochomotography | Right hand IPI variability | 0.027 seconds | Standard Deviation 0.07 |
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of IPI as Assessed by Dysdiadochomotography | Left hand IPI duration | 0.057 seconds | Standard Deviation 0.109 |
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of IPI as Assessed by Dysdiadochomotography | Right hand IPI duration | 0.079 seconds | Standard Deviation 0.105 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of IPI as Assessed by Dysdiadochomotography | Right hand IPI duration | 0.066 seconds | Standard Deviation 0.118 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of IPI as Assessed by Dysdiadochomotography | Left hand IPI variability | 0.049 seconds | Standard Deviation 0.046 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of IPI as Assessed by Dysdiadochomotography | Left hand IPI duration | 0.029 seconds | Standard Deviation 0.04 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of IPI as Assessed by Dysdiadochomotography | Right hand IPI variability | 0.131 seconds | Standard Deviation 0.219 |
Change From Baseline to Day 28 in the Mean Duration and Variability of IPI as Assessed by Pedomotography
Pedomotography was used to assess the tap duration and variability in a foot speeded tapping task. The patient placed their foot on the foot device such that the ball of the foot was positioned above a force transducer, and recordings were started after practice runs. The patient was then instructed to foot tap as fast as possible between 2 auditory cues. The beginning of a tap was defined as a rise of the force by 0.05 N above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. 5 trials of 10 seconds duration were performed with each foot. The mean changes from Baseline to Day 28 in the duration and variability of IPI for the left and right feet are presented as raw data. The statistical analyses present GLS mean ratios in the original units.
Time frame: Baseline (Day-1) to Day 28
Population: The PD population consisted of all subjects from the safety population who have not reported major protocol violations impacting Q-motor evaluation and who have a Q-motor evaluation assessed both at Baseline (Day -1) and at one post baseline visit.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of IPI as Assessed by Pedomotography | Left foot IPI variability | 0.115 seconds | Standard Deviation 0.248 |
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of IPI as Assessed by Pedomotography | Right foot IPI variability | 0.117 seconds | Standard Deviation 0.15 |
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of IPI as Assessed by Pedomotography | Left foot IPI duration | 0.117 seconds | Standard Deviation 0.383 |
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of IPI as Assessed by Pedomotography | Right foot IPI duration | 0.295 seconds | Standard Deviation 0.469 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of IPI as Assessed by Pedomotography | Right foot IPI duration | 0.073 seconds | Standard Deviation 0.158 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of IPI as Assessed by Pedomotography | Left foot IPI variability | -0.108 seconds | Standard Deviation 0.131 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of IPI as Assessed by Pedomotography | Left foot IPI duration | -0.123 seconds | Standard Deviation 0.206 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of IPI as Assessed by Pedomotography | Right foot IPI variability | 0.098 seconds | Standard Deviation 0.164 |
Change From Baseline to Day 28 in the Mean Duration and Variability of ITI as Assessed by Dysdiadochomotography
Dysdiadochomotography was used to assess the regularity of hand taps performed when alternating between the palm and dorsal surface of the hand performing a repetitive pronation/supination movement. The force and duration of the hand taps were recorded, with their hand positioned on a force transducer, and recordings were started after practice runs. The patient was then instructed to hand tap as fast as possible between 2 auditory cues. The beginning of a tap was defined as a rise of the force by 0.05 N above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. 5 trials of 10 seconds duration were performed with each hand. The mean changes from Baseline to Day 28 in the duration and variability of ITI for the left and right hands are presented as raw data. The statistical analyses present GLS mean ratios in the original units.
Time frame: Baseline (Day -1) to Day 28
Population: The PD population consisted of all subjects from the safety population who have not reported major protocol violations impacting Q-motor evaluation and who have a Q-motor evaluation assessed both at Baseline (Day -1) and at one post baseline visit.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of ITI as Assessed by Dysdiadochomotography | Left hand ITI variability | 0.036 seconds | Standard Deviation 0.061 |
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of ITI as Assessed by Dysdiadochomotography | Left hand ITI duration | 0.064 seconds | Standard Deviation 0.07 |
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of ITI as Assessed by Dysdiadochomotography | Right hand ITI variability | 0.053 seconds | Standard Deviation 0.082 |
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of ITI as Assessed by Dysdiadochomotography | Right hand ITI duration | 0.094 seconds | Standard Deviation 0.097 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of ITI as Assessed by Dysdiadochomotography | Right hand ITI variability | 0.017 seconds | Standard Deviation 0.018 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of ITI as Assessed by Dysdiadochomotography | Left hand ITI variability | 0.015 seconds | Standard Deviation 0.017 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of ITI as Assessed by Dysdiadochomotography | Right hand ITI duration | 0.022 seconds | Standard Deviation 0.014 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of ITI as Assessed by Dysdiadochomotography | Left hand ITI duration | 0.006 seconds | Standard Deviation 0.029 |
Change From Baseline to Day 28 in the Mean Duration and Variability of ITI as Assessed by Pedomotography
Pedomotography was used to assess the tap duration and variability in a foot speeded tapping task. The patient placed their foot on the foot device such that the ball of the foot was positioned above a force transducer, and recordings were started after practice runs. The patient was then instructed to foot tap as fast as possible between 2 auditory cues. The beginning of a tap was defined as a rise of the force by 0.05 N above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. 5 trials of 10 seconds duration were performed with each foot. The mean changes from Baseline to Day 28 in the duration and variability of ITI for the left and right feet are presented as raw data. The statistical analyses present GLS mean ratios in the original units.
Time frame: Baseline (Day-1) to Day 28
Population: The PD population consisted of all subjects from the safety population who have not reported major protocol violations impacting Q-motor evaluation and who have a Q-motor evaluation assessed both at Baseline (Day -1) and at one post baseline visit.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of ITI as Assessed by Pedomotography | Left foot ITI variability | 0.003 seconds | Standard Deviation 0.203 |
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of ITI as Assessed by Pedomotography | Right foot ITI variability | 0.023 seconds | Standard Deviation 0.118 |
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of ITI as Assessed by Pedomotography | Left foot ITI duration | -0.049 seconds | Standard Deviation 0.232 |
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of ITI as Assessed by Pedomotography | Right foot ITI duration | -0.016 seconds | Standard Deviation 0.121 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of ITI as Assessed by Pedomotography | Right foot ITI duration | -0.012 seconds | Standard Deviation 0.056 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of ITI as Assessed by Pedomotography | Left foot ITI variability | -0.047 seconds | Standard Deviation 0.108 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of ITI as Assessed by Pedomotography | Left foot ITI duration | -0.076 seconds | Standard Deviation 0.092 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of ITI as Assessed by Pedomotography | Right foot ITI variability | -0.016 seconds | Standard Deviation 0.089 |
Change From Baseline to Day 28 in the Mean Duration and Variability of Tap Durations (TD) as Assessed by Digitomotography
Digitomotography was used to assess the duration and the variability of TD in an index finger speeded tapping task. The patient placed their hand on a hand rest with their index finger positioned on a force transducer, and recordings were started after practice runs. The patient was then instructed to finger tap as fast as possible between 2 auditory cues. The beginning of a tap was defined as a rise of the force by 0.05 N above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. 5 trials of 10 seconds duration were performed with each hand. The mean changes from Baseline to Day 28 in the duration and variability of TD for the left and right hands are presented a raw data. The statistical analyses present GLS mean ratios in the original units.
Time frame: Baseline (Day -1) to Day 28
Population: The PD population consisted of all subjects from the safety population who have not reported major protocol violations impacting Q-motor evaluation and who have a Q-motor evaluation assessed both at Baseline (Day -1) and at one post baseline visit.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of Tap Durations (TD) as Assessed by Digitomotography | Left finger Variability of TD | 0.007 seconds | Standard Deviation 0.024 |
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of Tap Durations (TD) as Assessed by Digitomotography | Right finger Variability of TD | 0.017 seconds | Standard Deviation 0.016 |
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of Tap Durations (TD) as Assessed by Digitomotography | Left finger Duration of TD | 0.010 seconds | Standard Deviation 0.021 |
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of Tap Durations (TD) as Assessed by Digitomotography | Right finger Duration of TD | 0.012 seconds | Standard Deviation 0.021 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of Tap Durations (TD) as Assessed by Digitomotography | Right finger Duration of TD | 0.001 seconds | Standard Deviation 0.025 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of Tap Durations (TD) as Assessed by Digitomotography | Left finger Variability of TD | -0.007 seconds | Standard Deviation 0.015 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of Tap Durations (TD) as Assessed by Digitomotography | Left finger Duration of TD | -0.011 seconds | Standard Deviation 0.039 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of Tap Durations (TD) as Assessed by Digitomotography | Right finger Variability of TD | 0.012 seconds | Standard Deviation 0.017 |
Change From Baseline to Day 28 in the Mean Duration and Variability of TD as Assessed by Dysdiadochomotography
Dysdiadochomotography was used to assess the regularity of hand taps performed when alternating between the palm and dorsal surface of the hand performing a repetitive pronation/supination movement. The force and duration of the hand taps were recorded, with their hand positioned on a force transducer, and recordings were started after practice runs. The patient was then instructed to hand tap as fast as possible between 2 auditory cues. The beginning of a tap was defined as a rise of the force by 0.05 N above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. 5 trials of 10 seconds duration were performed with each hand. The mean changes from Baseline to Day 28 in the duration and variability of TD for the left and right hands are presented as raw data. The statistical analyses present GLS mean ratios in the original units.
Time frame: Baseline (Day -1) to Day 28
Population: The PD population consisted of all subjects from the safety population who have not reported major protocol violations impacting Q-motor evaluation and who have a Q-motor evaluation assessed both at Baseline (Day -1) and at one post baseline visit.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of TD as Assessed by Dysdiadochomotography | Left hand variability of TD | 0.001 seconds | Standard Deviation 0.138 |
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of TD as Assessed by Dysdiadochomotography | Right hand variability of TD | -0.012 seconds | Standard Deviation 0.073 |
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of TD as Assessed by Dysdiadochomotography | Left hand duration of TD | -0.006 seconds | Standard Deviation 0.088 |
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of TD as Assessed by Dysdiadochomotography | Right hand duration of TD | -0.019 seconds | Standard Deviation 0.089 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of TD as Assessed by Dysdiadochomotography | Right hand duration of TD | 0.022 seconds | Standard Deviation 0.069 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of TD as Assessed by Dysdiadochomotography | Left hand variability of TD | 0.023 seconds | Standard Deviation 0.026 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of TD as Assessed by Dysdiadochomotography | Left hand duration of TD | 0.017 seconds | Standard Deviation 0.027 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of TD as Assessed by Dysdiadochomotography | Right hand variability of TD | 0.078 seconds | Standard Deviation 0.128 |
Change From Baseline to Day 28 in the Mean Duration and Variability of TD as Assessed by Pedomotography
Pedomotography was used to assess the tap duration and variability in a foot speeded tapping task. The patient placed their foot on the foot device such that the ball of the foot was positioned above a force transducer, and recordings were started after practice runs. The patient was then instructed to foot tap as fast as possible between 2 auditory cues. The patient was then instructed to foot tap as fast as possible between 2 auditory cues. The beginning of a tap was defined as a rise of the force by 0.05 N above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. 5 trials of 10 seconds duration were performed with each foot. The mean changes from Baseline to Day 28 in the duration and variability of TD for the left and right feet are presented as raw data. The statistical analyses present GLS mean ratios in the original units.
Time frame: Baseline (Day-1) to Day 28
Population: The PD population consisted of all subjects from the safety population who have not reported major protocol violations impacting Q-motor evaluation and who have a Q-motor evaluation assessed both at Baseline (Day -1) and at one post baseline visit.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of TD as Assessed by Pedomotography | Left foot TD variability | 0.225 seconds | Standard Deviation 0.332 |
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of TD as Assessed by Pedomotography | Left foot TD duration | 0.179 seconds | Standard Deviation 0.28 |
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of TD as Assessed by Pedomotography | Right foot TD duration | 0.358 seconds | Standard Deviation 0.609 |
| BN82451B | Change From Baseline to Day 28 in the Mean Duration and Variability of TD as Assessed by Pedomotography | Right foot TD variability | 0.306 seconds | Standard Deviation 0.566 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of TD as Assessed by Pedomotography | Right foot TD duration | 0.083 seconds | Standard Deviation 0.133 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of TD as Assessed by Pedomotography | Left foot TD variability | -0.056 seconds | Standard Deviation 0.058 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of TD as Assessed by Pedomotography | Right foot TD variability | 0.105 seconds | Standard Deviation 0.14 |
| Placebo | Change From Baseline to Day 28 in the Mean Duration and Variability of TD as Assessed by Pedomotography | Left foot TD duration | -0.040 seconds | Standard Deviation 0.106 |
Change From Baseline to Day 28 in the Mean Grip Force Variability as Determined by Manumotography
The coordination of isometric grip forces in the precision grip between the thumb and index finger were assessed by Manumotography. Grip forces were assessed during grip initiation, object transport and in a static holding phase. Subjects were instructed to grasp and lift a device equipped with a force transducer and 3D position sensor in the precision grip between thumb and index finger and hold it stable adjacent to a marker 10 centimetres high. Grip forces and 3D position and orientation of the object were recorded. Mean isometric grip forces and grip force variability in the static phase (expressed as coefficient of variation = standard deviation/mean x 100 \[GFV-C\]) were calculated during a 15 second period. 5 trials of 20 seconds duration were performed with each hand. The mean changes from Baseline to Day 28 in the grip force variability of each hand are presented as raw data. The statistical analyses present GLS mean ratios in the original units.
Time frame: Baseline (Day -1) to Day 28
Population: The PD population consisted of all subjects from the safety population who have not reported major protocol violations impacting Q-motor evaluation and who have a Q-motor evaluation assessed both at Baseline (Day -1) and at one post baseline visit.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| BN82451B | Change From Baseline to Day 28 in the Mean Grip Force Variability as Determined by Manumotography | Left hand grip force variability | 5.74 percentage of variation | Standard Deviation 4.38 |
| BN82451B | Change From Baseline to Day 28 in the Mean Grip Force Variability as Determined by Manumotography | Right hand grip force variability | 5.82 percentage of variation | Standard Deviation 7.94 |
| Placebo | Change From Baseline to Day 28 in the Mean Grip Force Variability as Determined by Manumotography | Right hand grip force variability | 2.35 percentage of variation | Standard Deviation 1.17 |
| Placebo | Change From Baseline to Day 28 in the Mean Grip Force Variability as Determined by Manumotography | Left hand grip force variability | 2.61 percentage of variation | Standard Deviation 4.57 |
Change From Baseline to Day 28 in the Mean Isometric Grip Forces as Determined by Manumotography
The coordination of isometric grip forces in the precision grip between the thumb and index finger were assessed by Manumotography. Grip forces were assessed during grip initiation, object transport and in a static holding phase. Subjects were instructed to grasp and lift a device equipped with a force transducer and 3D position sensor in the precision grip between thumb and index finger and hold it stable adjacent to a marker 10 centimetres high. Grip forces and 3D position and orientation of the object were recorded. Mean isometric grip forces and grip force variability in the static phase (expressed as coefficient of variation = standard deviation/mean x 100 \[GFV-C\]) were calculated during a 15 second period. 5 trials of 20 seconds duration were performed with each hand. The mean changes from Baseline to Day 28 in the mean isometric grip forces of each hand are presented as raw data. The statistical analyses present GLS mean ratios in the original units.
Time frame: Baseline (Day -1) to Day 28
Population: The PD population consisted of all subjects from the safety population who have not reported major protocol violations impacting Q-motor evaluation and who have a Q-motor evaluation assessed both at Baseline (Day -1) and at one post baseline visit.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| BN82451B | Change From Baseline to Day 28 in the Mean Isometric Grip Forces as Determined by Manumotography | Left hand isometric grip forces | -0.75 Newton | Standard Deviation 2.86 |
| BN82451B | Change From Baseline to Day 28 in the Mean Isometric Grip Forces as Determined by Manumotography | Right hand isometric grip forces | -2.06 Newton | Standard Deviation 6 |
| Placebo | Change From Baseline to Day 28 in the Mean Isometric Grip Forces as Determined by Manumotography | Right hand isometric grip forces | 0.91 Newton | Standard Deviation 1.67 |
| Placebo | Change From Baseline to Day 28 in the Mean Isometric Grip Forces as Determined by Manumotography | Left hand isometric grip forces | 1.55 Newton | Standard Deviation 1.99 |
Change From Baseline to Day 28 in the Mean Tapping Frequency as Assessed by Dysdiadochomotography
Dysdiadochomotography was used to assess the regularity of hand taps performed when alternating between the palm and dorsal surface of the hand performing a repetitive pronation/supination movement. The force and duration of the hand taps were recorded, with their hand positioned on a force transducer, and recordings were started after practice runs. The patient was then instructed to hand tap as fast as possible between 2 auditory cues. The beginning of a tap was defined as a rise of the force by 0.05 N above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. 5 trials of 10 seconds duration were performed with each hand. The tapping frequency was calculated as the number of taps between the onsets of the first and the last tap divided by the time in between. The mean changes from Baseline to Day 28 in the tapping frequency for the left and right hands are presented as raw data. GLS mean ratios are in original units.
Time frame: Baseline (Day -1) to Day 28
Population: The PD population consisted of all subjects from the safety population who have not reported major protocol violations impacting Q-motor evaluation and who have a Q-motor evaluation assessed both at Baseline (Day -1) and at one post baseline visit.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| BN82451B | Change From Baseline to Day 28 in the Mean Tapping Frequency as Assessed by Dysdiadochomotography | Left hand freq | -0.185 Hertz | Standard Deviation 0.402 |
| BN82451B | Change From Baseline to Day 28 in the Mean Tapping Frequency as Assessed by Dysdiadochomotography | Right hand freq | -0.236 Hertz | Standard Deviation 0.349 |
| Placebo | Change From Baseline to Day 28 in the Mean Tapping Frequency as Assessed by Dysdiadochomotography | Left hand freq | -0.073 Hertz | Standard Deviation 0.088 |
| Placebo | Change From Baseline to Day 28 in the Mean Tapping Frequency as Assessed by Dysdiadochomotography | Right hand freq | -0.121 Hertz | Standard Deviation 0.189 |
Change From Baseline to Day 28 in the Mean Tapping Frequency as Assessed by Pedomotography
Pedomotography was used to assess the tap duration and variability in a foot speeded tapping task. The patient placed their foot on the foot device such that the ball of the foot was positioned above a force transducer, and recordings were started after practice runs. The patient was then instructed to foot tap as fast as possible between 2 auditory cues. The beginning of a tap was defined as a rise of the force by 0.05 N above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. 5 trials of 10 seconds duration were performed with each foot. The tapping frequency was calculated as the number of taps between the onsets of the first and the last tap divided by the time in between. The mean changes from Baseline to Day 28 in the tapping frequency for the left and right hands are presented as raw data. The statistical analyses present GLS mean ratios in the original units.
Time frame: Baseline (Day -1) to Day 28
Population: The PD population consisted of all subjects from the safety population who have not reported major protocol violations impacting Q-motor evaluation and who have a Q-motor evaluation assessed both at Baseline (Day -1) and at one post baseline visit.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| BN82451B | Change From Baseline to Day 28 in the Mean Tapping Frequency as Assessed by Pedomotography | Left foot freq | -0.259 Hertz | Standard Deviation 0.513 |
| BN82451B | Change From Baseline to Day 28 in the Mean Tapping Frequency as Assessed by Pedomotography | Right foot freq | -0.383 Hertz | Standard Deviation 0.481 |
| Placebo | Change From Baseline to Day 28 in the Mean Tapping Frequency as Assessed by Pedomotography | Left foot freq | 0.556 Hertz | Standard Deviation 0.678 |
| Placebo | Change From Baseline to Day 28 in the Mean Tapping Frequency as Assessed by Pedomotography | Right foot freq | -0.18 Hertz | Standard Deviation 0.55 |
Change From Baseline to Day 28 in the Mean Tapping Frequency (Freq) as Assessed by Digitomotography
Digitomotography was used to assess the duration and the variability of TD in an index finger speeded tapping task. The patient placed their hand on a hand rest with their index finger positioned on a force transducer, and recordings were started after practice runs. The patient was then instructed to finger tap as fast as possible between 2 auditory cues. The beginning of a tap was defined as a rise of the force by 0.05 N above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. 5 trials of 10 seconds duration were performed with each hand. The tapping frequency was calculated as the number of taps between the onsets of the first and the last tap divided by the time in between. The mean changes from Baseline to Day 28 in the tapping frequency for the left and right hands are presented as raw data. The statistical analyses present GLS mean ratios in the original units.
Time frame: Baseline (Day-1) to Day 28
Population: The PD population consisted of all subjects from the safety population who have not reported major protocol violations impacting Q-motor evaluation and who have a Q-motor evaluation assessed both at Baseline (Day -1) and at one post baseline visit.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| BN82451B | Change From Baseline to Day 28 in the Mean Tapping Frequency (Freq) as Assessed by Digitomotography | Left finger freq | -0.492 Hertz | Standard Deviation 0.382 |
| BN82451B | Change From Baseline to Day 28 in the Mean Tapping Frequency (Freq) as Assessed by Digitomotography | Right finger freq | -0.466 Hertz | Standard Deviation 0.389 |
| Placebo | Change From Baseline to Day 28 in the Mean Tapping Frequency (Freq) as Assessed by Digitomotography | Left finger freq | -0.001 Hertz | Standard Deviation 0.315 |
| Placebo | Change From Baseline to Day 28 in the Mean Tapping Frequency (Freq) as Assessed by Digitomotography | Right finger freq | -0.365 Hertz | Standard Deviation 0.231 |
Change From Baseline to Day 28 in the Mean Variability of Peak Tapping Forces (TF) as Assessed by Digitomotography
Digitomotography was used to assess the duration and the variability of TD in an index finger speeded tapping task. The patient placed their hand on a hand rest with their index finger positioned on a force transducer, and recordings were started after practice runs. The patient was then instructed to finger tap as fast as possible between 2 auditory cues. The beginning of a tap was defined as a rise of the force by 0.05 N above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. 5 trials of 10 seconds duration were performed with each hand. The mean changes from Baseline to Day 28 in the variability of TF for the left and right hands are presented as raw data. The statistical analyses present GLS mean ratios in the original units.
Time frame: Baseline (Day-1) to Day 28
Population: The PD population consisted of all subjects from the safety population who have not reported major protocol violations impacting Q-motor evaluation and who have a Q-motor evaluation assessed both at Baseline (Day -1) and at one post baseline visit.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| BN82451B | Change From Baseline to Day 28 in the Mean Variability of Peak Tapping Forces (TF) as Assessed by Digitomotography | Left finger TF | 0.65 percentage of variation | Standard Deviation 6.97 |
| BN82451B | Change From Baseline to Day 28 in the Mean Variability of Peak Tapping Forces (TF) as Assessed by Digitomotography | Right finger TF | 3.75 percentage of variation | Standard Deviation 12.86 |
| Placebo | Change From Baseline to Day 28 in the Mean Variability of Peak Tapping Forces (TF) as Assessed by Digitomotography | Left finger TF | -6.43 percentage of variation | Standard Deviation 6.26 |
| Placebo | Change From Baseline to Day 28 in the Mean Variability of Peak Tapping Forces (TF) as Assessed by Digitomotography | Right finger TF | -0.11 percentage of variation | Standard Deviation 8.26 |
Change From Baseline to Day 28 in the Mean Variability of Peak TF as Assessed by Dysdiadochomotography
Dysdiadochomotography was used to assess the regularity of hand taps performed when alternating between the palm and dorsal surface of the hand performing a repetitive pronation/supination movement. The force and duration of the hand taps were recorded, with their hand positioned on a force transducer, and recordings were started after practice runs. The patient was then instructed to hand tap as fast as possible between 2 auditory cues. The beginning of a tap was defined as a rise of the force by 0.05 N above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. 5 trials of 10 seconds duration were performed with each hand. The mean changes from Baseline to Day 28 in the variability of TF for the left and right hands are presented as raw data. The statistical analyses present GLS mean ratios in the original units.
Time frame: Baseline (Day-1) to Day 28
Population: The PD population consisted of all subjects from the safety population who have not reported major protocol violations impacting Q-motor evaluation and who have a Q-motor evaluation assessed both at Baseline (Day -1) and at one post baseline visit.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| BN82451B | Change From Baseline to Day 28 in the Mean Variability of Peak TF as Assessed by Dysdiadochomotography | Left hand TF variability | 3.50 percentage of variation | Standard Deviation 7.44 |
| BN82451B | Change From Baseline to Day 28 in the Mean Variability of Peak TF as Assessed by Dysdiadochomotography | Right hand TF variability | 2.5 percentage of variation | Standard Deviation 10.87 |
| Placebo | Change From Baseline to Day 28 in the Mean Variability of Peak TF as Assessed by Dysdiadochomotography | Left hand TF variability | 9.98 percentage of variation | Standard Deviation 2.22 |
| Placebo | Change From Baseline to Day 28 in the Mean Variability of Peak TF as Assessed by Dysdiadochomotography | Right hand TF variability | 3.61 percentage of variation | Standard Deviation 2.42 |
Change From Baseline to Day 28 in the Mean Variability of Peak TF as Assessed by Pedomotography
Pedomotography was used to assess the tap duration and variability in a foot speeded tapping task. The patient placed their foot on the foot device such that the ball of the foot was positioned above a force transducer, and recordings were started after practice runs. The patient was then instructed to foot tap as fast as possible between 2 auditory cues. The beginning of a tap was defined as a rise of the force by 0.05 N above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. 5 trials of 10 seconds duration were performed with each foot. The mean changes from Baseline to Day 28 in the variability of TF for the left and right feet are presented as raw data. The statistical analyses present GLS mean ratios in the original units.
Time frame: Baseline (Day -1) to Day 28
Population: The PD population consisted of all subjects from the safety population who have not reported major protocol violations impacting Q-motor evaluation and who have a Q-motor evaluation assessed both at Baseline (Day -1) and at one post baseline visit.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| BN82451B | Change From Baseline to Day 28 in the Mean Variability of Peak TF as Assessed by Pedomotography | Left foot TF variability | 11.63 percentage of variation | Standard Deviation 16.38 |
| BN82451B | Change From Baseline to Day 28 in the Mean Variability of Peak TF as Assessed by Pedomotography | Right foot TF variability | -2.52 percentage of variation | Standard Deviation 22.35 |
| Placebo | Change From Baseline to Day 28 in the Mean Variability of Peak TF as Assessed by Pedomotography | Left foot TF variability | -20.19 percentage of variation | Standard Deviation 34.3 |
| Placebo | Change From Baseline to Day 28 in the Mean Variability of Peak TF as Assessed by Pedomotography | Right foot TF variability | -18.31 percentage of variation | Standard Deviation 6.52 |
Change From Baseline to Day 28 in the Orientation-index as Determined by Choreomotography
Choreatic (involuntary) movements were assessed using Choreomotography by calculating a position-index and orientation-index. Patients were asked to grasp and lift a device equipped with an electromagnetic sensor, and were asked to hold the device as stable as possible. 3D changes in position (x, y and z) and orientation (roll, pitch and yaw) were recorded and used to calculate a position-index and an orientation-index. This method provided an objective measure of the involuntary movements. 5 trials of 20 seconds duration were performed with each hand, and the start and end of each trial was signalled by a cueing tone. The mean changes from Baseline to Day 28 in the orientation-index of the right and left hands are presented as raw data. The statistical analyses present GLS mean ratios in the original units.
Time frame: Baseline (Day -1) to Day 28
Population: The PD population consisted of all subjects from the safety population who have not reported major protocol violations impacting Q-motor evaluation and who have a Q-motor evaluation assessed both at Baseline (Day -1) and at one post baseline visit.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| BN82451B | Change From Baseline to Day 28 in the Orientation-index as Determined by Choreomotography | Left hand orientation-index | 0.131 radians per second (radians/s) | Standard Deviation 0.125 |
| BN82451B | Change From Baseline to Day 28 in the Orientation-index as Determined by Choreomotography | Right hand orientation-index | 0.098 radians per second (radians/s) | Standard Deviation 0.087 |
| Placebo | Change From Baseline to Day 28 in the Orientation-index as Determined by Choreomotography | Right hand orientation-index | 0.054 radians per second (radians/s) | Standard Deviation 0.045 |
| Placebo | Change From Baseline to Day 28 in the Orientation-index as Determined by Choreomotography | Left hand orientation-index | 0.082 radians per second (radians/s) | Standard Deviation 0.1 |
Change From Baseline to Day 28 in the Position-index as Determined by Choreomotography
Choreatic (involuntary) movements were assessed using Choreomotography by calculating a position-index and orientation-index. Patients were asked to grasp and lift a device equipped with an electromagnetic sensor, and were asked to hold the device as stable as possible. Three dimensional (3D) changes in position (x, y and z) and orientation (roll, pitch and yaw) were recorded and used to calculate a position-index and an orientation-index. This method provided an objective measure of the involuntary movements. 5 trials of 20 seconds duration were performed with each hand, and the start and end of each trial was signalled by a cueing tone. The mean changes from Baseline to Day 28 in the position-index of the right and left hands are presented as raw data. The statistical analyses present geometric least squares (GLS) mean ratios in the original units.
Time frame: Baseline (Day-1) to Day 28
Population: The Pharmacodynamic (PD) population consisted of all subjects from the safety population who have not reported major protocol violations impacting quantitative measures of motor function (Q-motor) evaluation and who have a Q-motor evaluation assessed both at Baseline (Day -1) and at one post baseline visit.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| BN82451B | Change From Baseline to Day 28 in the Position-index as Determined by Choreomotography | Left hand position-index | 0.021 metres per second (m/s) | Standard Deviation 0.024 |
| BN82451B | Change From Baseline to Day 28 in the Position-index as Determined by Choreomotography | Right hand position-index | 0.018 metres per second (m/s) | Standard Deviation 0.014 |
| Placebo | Change From Baseline to Day 28 in the Position-index as Determined by Choreomotography | Left hand position-index | 0.009 metres per second (m/s) | Standard Deviation 0.007 |
| Placebo | Change From Baseline to Day 28 in the Position-index as Determined by Choreomotography | Right hand position-index | 0.009 metres per second (m/s) | Standard Deviation 0.006 |
Peak Plasma Concentration (Cmax)
Cmax was determined for BN82451B and its metabolites BN2468 and BN7167 on Days 1, 14 and 28. Day 1 data represent the PK after the first dose (Cmax). The data for Days 14 and 28 represent the Cmax at steady state (Cmax,ss) at the initial cohort dose and following dose escalation, respectively. Data is presented for cohorts 1 and 2, as the study terminated prior to dosing of cohort 3.
Time frame: Days 1, 14 and 28
Population: The PK population consisted of all subjects from the safety population who had no major protocol deviations affecting the PK variables and who had a sufficient number of plasma BN82451B concentrations to estimate the main PK parameters.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| BN82451B | Peak Plasma Concentration (Cmax) | Day 1 BN2468 Cmax | 9.03 ng/mL | Standard Deviation 4.14 |
| BN82451B | Peak Plasma Concentration (Cmax) | Day 14 BN7167 Cmax,ss | 4.90 ng/mL | Standard Deviation 2.35 |
| BN82451B | Peak Plasma Concentration (Cmax) | Day 14 BN82451B Cmax,ss | 162.88 ng/mL | Standard Deviation 56.31 |
| BN82451B | Peak Plasma Concentration (Cmax) | Day 28 BN82451B Cmax,ss | 251.77 ng/mL | Standard Deviation 105.64 |
| BN82451B | Peak Plasma Concentration (Cmax) | Day 1 BN7167 Cmax | 3.62 ng/mL | Standard Deviation 1.62 |
| BN82451B | Peak Plasma Concentration (Cmax) | Day 28 BN2468 Cmax,ss | 135.19 ng/mL | Standard Deviation 5.06 |
| BN82451B | Peak Plasma Concentration (Cmax) | Day 14 BN2468 Cmax,ss | 75.34 ng/mL | Standard Deviation 15.16 |
| BN82451B | Peak Plasma Concentration (Cmax) | Day 28 BN 7167 Cmax,ss | 5.51 ng/mL | Standard Deviation 1.82 |
| BN82451B | Peak Plasma Concentration (Cmax) | Day 1 BN82451B Cmax | 71.61 ng/mL | Standard Deviation 14.81 |
| Placebo | Peak Plasma Concentration (Cmax) | Day 28 BN 7167 Cmax,ss | 9.54 ng/mL | Standard Deviation 6.92 |
| Placebo | Peak Plasma Concentration (Cmax) | Day 1 BN82451B Cmax | 101.45 ng/mL | Standard Deviation 16.25 |
| Placebo | Peak Plasma Concentration (Cmax) | Day 1 BN2468 Cmax | 18.87 ng/mL | Standard Deviation 13 |
| Placebo | Peak Plasma Concentration (Cmax) | Day 1 BN7167 Cmax | 5.61 ng/mL | Standard Deviation 3.62 |
| Placebo | Peak Plasma Concentration (Cmax) | Day 14 BN82451B Cmax,ss | 271.64 ng/mL | Standard Deviation 99.9 |
| Placebo | Peak Plasma Concentration (Cmax) | Day 14 BN2468 Cmax,ss | 125.34 ng/mL | Standard Deviation 38.13 |
| Placebo | Peak Plasma Concentration (Cmax) | Day 14 BN7167 Cmax,ss | 6.28 ng/mL | Standard Deviation 3.55 |
| Placebo | Peak Plasma Concentration (Cmax) | Day 28 BN82451B Cmax,ss | 340.41 ng/mL | Standard Deviation 156.61 |
| Placebo | Peak Plasma Concentration (Cmax) | Day 28 BN2468 Cmax,ss | 171.64 ng/mL | Standard Deviation 47.64 |
Time to Peak Plasma Concentration (Tmax)
Tmax is the empirical time of Cmax and was determined for BN82451B and its metabolites BN2468 and BN7167 on Days 1, 14 and 28. Day 1 data represent the PK after the first dose (Tmax). The data for Days 14 and 28 represent the Tmax at steady state (Tmax,ss) at the initial cohort dose and following dose escalation, respectively. Data is presented for cohorts 1 and 2, as the study terminated prior to dosing of cohort 3.
Time frame: Days 1, 14 and 28
Population: The PK population consisted of all subjects from the safety population who had no major protocol deviations affecting the PK variables and who had a sufficient number of plasma BN82451B concentrations to estimate the main PK parameters.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| BN82451B | Time to Peak Plasma Concentration (Tmax) | Day 14 BN2468 Tmax,ss | 4 hours |
| BN82451B | Time to Peak Plasma Concentration (Tmax) | Day 1 BN7167 Tmax | 1.00 hours |
| BN82451B | Time to Peak Plasma Concentration (Tmax) | Day 14 BN7167 Tmax,ss | 1 hours |
| BN82451B | Time to Peak Plasma Concentration (Tmax) | Day 1 BN2468 Tmax | 9.98 hours |
| BN82451B | Time to Peak Plasma Concentration (Tmax) | Day 28 BN82451B Tmax,ss | 3 hours |
| BN82451B | Time to Peak Plasma Concentration (Tmax) | Day 28 BN2468 Tmax,ss | 4.06 hours |
| BN82451B | Time to Peak Plasma Concentration (Tmax) | Day 14 BN82451B Tmax,ss | 3.0 hours |
| BN82451B | Time to Peak Plasma Concentration (Tmax) | Day 28 BN7167 Tmax,ss | 1 hours |
| BN82451B | Time to Peak Plasma Concentration (Tmax) | Day 1 BN82451B Tmax | 3.0 hours |
| Placebo | Time to Peak Plasma Concentration (Tmax) | Day 28 BN7167 Tmax,ss | 1.52 hours |
| Placebo | Time to Peak Plasma Concentration (Tmax) | Day 1 BN82451B Tmax | 2.51 hours |
| Placebo | Time to Peak Plasma Concentration (Tmax) | Day 1 BN2468 Tmax | 11.92 hours |
| Placebo | Time to Peak Plasma Concentration (Tmax) | Day 1 BN7167 Tmax | 1.00 hours |
| Placebo | Time to Peak Plasma Concentration (Tmax) | Day 14 BN82451B Tmax,ss | 3.0 hours |
| Placebo | Time to Peak Plasma Concentration (Tmax) | Day 14 BN2468 Tmax,ss | 2.51 hours |
| Placebo | Time to Peak Plasma Concentration (Tmax) | Day 14 BN7167 Tmax,ss | 1 hours |
| Placebo | Time to Peak Plasma Concentration (Tmax) | Day 28 BN2468 Tmax,ss | 2.06 hours |
| Placebo | Time to Peak Plasma Concentration (Tmax) | Day 28 BN82451B Tmax,ss | 2.56 hours |